HUTCHMED (CHINA) LIMITED - AMERICAN DEPOSITARY SHA

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025

23 4 2025 20:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China

21 4 2025 20:00:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months Low: HUTCHMED (CHINA) LIMITED - AMERICAN DEPOSITARY SHA

09 4 2025 11:05:34 提供 NetDania Notify

NetDania - New 12 months Low: HUTCHMED (CHINA) LIMITED - AMERICAN DEPOSITARY SHA

08 4 2025 13:42:49 提供 NetDania Notify

NetDania - New 12 months Low: HUTCHMED (CHINA) LIMITED - AMERICAN DEPOSITARY SHA

07 4 2025 09:45:30 提供 NetDania Notify

HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma

21 3 2025 06:00:00 提供 Nasdaq GlobeNewswire

Intended Retirement of Independent Non-executive Directors and changes of composition of board committees

20 3 2025 05:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025

19 3 2025 20:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Reports 2024 Full Year Results and Provides Business Updates

19 3 2025 07:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China

18 3 2025 20:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China

06 3 2025 05:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

05 3 2025 05:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED to Announce 2024 Final Results

19 2 2025 03:30:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months Low: HUTCHMED (CHINA) LIMITED - AMERICAN DEPOSITARY SHA

12 2 2025 09:46:46 提供 NetDania Notify

HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

13 1 2025 23:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy

01 1 2025 19:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture

01 1 2025 05:46:43 提供 Nasdaq GlobeNewswire

HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)

12 12 2024 19:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy

11 12 2024 23:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer

03 12 2024 05:00:00 提供 Nasdaq GlobeNewswire